Compare HRMY & DNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HRMY | DNN |
|---|---|---|
| Founded | 2017 | 1954 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Metals and Minerals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.5B |
| IPO Year | 2020 | 1997 |
| Metric | HRMY | DNN |
|---|---|---|
| Price | $37.82 | $2.69 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $51.33 | N/A |
| AVG Volume (30 Days) | 695.1K | ★ 39.0M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.44 | N/A |
| EPS | ★ 3.17 | N/A |
| Revenue | ★ $825,944,000.00 | $3,493,456.00 |
| Revenue This Year | $23.11 | $197.29 |
| Revenue Next Year | $16.15 | $55.12 |
| P/E Ratio | $12.04 | ★ N/A |
| Revenue Growth | 21.13 | ★ 23.35 |
| 52 Week Low | $25.52 | $1.08 |
| 52 Week High | $40.93 | $3.42 |
| Indicator | HRMY | DNN |
|---|---|---|
| Relative Strength Index (RSI) | 54.65 | 52.23 |
| Support Level | $37.12 | $2.48 |
| Resistance Level | $39.60 | $2.89 |
| Average True Range (ATR) | 1.15 | 0.14 |
| MACD | -0.38 | 0.01 |
| Stochastic Oscillator | 17.33 | 53.66 |
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Denison Mines Corp is a uranium exploration and development company focused on the Athabasca Basin region of northern Saskatchewan, Canada. The company holds a noteworthy 95% interest in its flagship Wheeler River Uranium Project, the undeveloped uranium project located in the infrastructure-rich eastern part of the Athabasca Basin. Additionally, it is involved in mine decommissioning and environmental services through its Closed Mines group, which manages the Elliot Lake reclamation projects and offers third-party post-closure mine care and maintenance services. The Company operates in two main segments: the Mining segment and the Corporate and Other segment. The majority of revenue is generated from the mining segment.